BGBIO.OL Live signaler | Maksimer profitt med Getagraph.com

SELG 1277 min ago

@ NOK0.146

Utstedt: 26 apr 2024 @ 12:46

Avkastning: 3.16%

Forrige signal: apr 24 - 12:08

Forrige signal: Kjøp

Avkastning: -8.76 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 16:25):
Our systems believe the stock currently is undervalued by 1.57% compare to its pairs and should correct upwards.

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases...

Stats
Dagens volum	87.23M
Gjennomsnittsvolum	43.03M
Markedsverdi	419.44M
EPS	NOK0 ( 2024-02-15 )
Neste inntjeningsdato	( NOK-0.0200 ) 2024-05-23
Last Dividend	NOK0 ( N/A )
Next Dividend	NOK0 ( N/A )
P/E	-0.270
ATR14	NOK0.0170 (11.26%)

Korrelasjon (AI algo v.1.1b): Undervalued: 1.57% NOK0.153 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: -0.83 (strong negative)

Kort: 0.16 (neutral)

Signal:(34) Neutral

BerGenBio ASA Korrelasjon

10 Mest positive korrelasjoner
PLT.OL	0.937
ELIMP.OL	0.935
KMCP.OL	0.931
TRVX.OL	0.925
ELABS.OL	0.908
ABG.OL	0.895
AKER.OL	0.893
VOW.OL	0.892
SADG.OL	0.891
EFUEL.OL	0.884

10 Mest negative korrelasjoner
AYFIE.OL	-0.95
ATEA.OL	-0.929
TECH.OL	-0.886
ELK.OL	-0.885
BAKKA.OL	-0.882
BWO.OL	-0.877
PEXIP.OL	-0.871
BOUV.OL	-0.865
GOD.OL	-0.864
SMOP.OL	-0.862

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

BerGenBio ASA Korrelasjon - Valuta/Råvare

-0.76
( moderate negative )

-0.69
( moderate negative )

0.00
( neutral )

0.43
( neutral )

BerGenBio ASA Økonomi

Annual	2022
Omsetning:	NOK389 000
Bruttogevinst:	NOK389 000 (100.00 %)
EPS:	NOK-0.390

FY	2022
Omsetning:	NOK389 000
Bruttogevinst:	NOK389 000 (100.00 %)
EPS:	NOK-0.390

FY	2021
Omsetning:	NOK774 000
Bruttogevinst:	NOK0.00 (0.00 %)
EPS:	NOK-3.52

FY	2020
Omsetning:	NOK601 000
Bruttogevinst:	NOK0.00 (0.00 %)
EPS:	NOK-3.43

Financial Reports:

No articles found.

BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.